Tuhura Biosciences and Kintara Therapeutics Announce Positive Results From Phase 1B Trial of Ifx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (Mcc) and Cutaneous Squamous Cell Carcinoma (Cscc)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.